iBio (IBIO) Return on Capital Employed (2011 - 2026)
iBio (IBIO) posted quarterly Return on Capital Employed of 42.21% for Q1 2026, up 6986.0% year-over-year from 0.6% in Q1 2025, and up 3.28% quarter-over-quarter from 43.64% in Q4 2025.
iBio (IBIO) Return on Capital Employed (2011 - 2026) Analysis & Trends
iBio (IBIO) has reported Return on Capital Employed for 16 consecutive years, with 42.21% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 6986.0% year-over-year to 42.21%; the TTM figure through Mar 2026 stood at 42.21% (up 6986.0% YoY), while the FY2025 annual figure was 93.7%, down 4026.0% from the prior year.
- Return on Capital Employed improved to 42.21% in Q1 2026 per IBIO's latest filing, from 43.64% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 25.47% in Q1 2022 and bottomed at 145.02% in Q4 2023.
- Historically, Return on Capital Employed has averaged 84.31% across 5 years, with a median of 84.57% in 2024.
- Annual changes were most pronounced in 2023 — Return on Capital Employed plunged 10945 bps — and 2024, when it jumped 9512 bps.
- iBio's Return on Capital Employed stood at 87.73% in 2022, then sank by 65 bps to 145.02% in 2023, then surged by 42 bps to 84.57% in 2024, then jumped by 48 bps to 43.64% in 2025, then increased by 3 bps to 42.21% in 2026.
- Business Quant data shows IBIO's Return on Capital Employed at 42.21% in Q1 2026, 43.64% in Q4 2025, and 54.35% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.71 Bn | 130.86 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.60 Bn | 77.60 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.82 Bn | 59.63 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.92 Bn | 52.79 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.88 Bn | 36.78 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.46 Bn | 28.15 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.96 Bn | 9.57 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -42.21% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.21% |
| Dec 31, 2025 | -43.64% |
| Sep 30, 2025 | -54.35% |
| Jun 30, 2025 | -123.70% |
| Mar 31, 2025 | -112.06% |
| Dec 31, 2024 | -84.57% |
| Sep 30, 2024 | -67.53% |
| Jun 30, 2024 | -46.72% |
| Mar 31, 2024 | -88.04% |
| Dec 31, 2023 | -145.02% |
| Sep 30, 2023 | -143.10% |
| Jun 30, 2023 | -141.84% |
| Mar 31, 2023 | -134.91% |
| Dec 31, 2022 | -87.73% |
| Sep 30, 2022 | -53.70% |
| Jun 30, 2022 | -38.59% |
| Mar 31, 2022 | -25.47% |
| Dec 31, 2021 | -22.96% |
| Sep 30, 2021 | -21.43% |
| Jun 30, 2021 | -22.51% |